New-onset Diabetes as an Early Sign of Pancreatic Cancer

Jemma Ahn; Jong Kyun Lee

doi:10.4166/kjg.2013.62.5.263

Journal List > Korean J Gastroenterol > v.62(5) > 1007154

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ahn and Lee: New-onset Diabetes as an Early Sign of Pancreatic Cancer

Review Article

Korean J Gastroenterol 2013;62(5):263-266.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.5.263

New-onset Diabetes as an Early Sign of Pancreatic Cancer

Jemma Ahn, Jong Kyun Lee

Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to: Jong Kyun Lee, Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-3409, Fax: +82-2-3410-6983, E-mail: jongk.lee@samsung.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

While long-standing diabetes is a risk factor of pancreatic cancer, new-onset diabetes could be a consequence of underlying pancreatic malignancy. About 30% to 50% of pancreatic cancer patients have new-onset diabetes. Because diabetes develops in preclinical or early stages of pancreatic cancer, it could serve as an excellent clue for early detection of pancreatic cancer. Insulin resistance associated with hyperglycemia and hyperinsulinemia by diabetogenic factors secreted from cancer cells have been suggested to be a possible mechanism of pancreatic cancer-induced diabetes. It is difficult to differentiate pancreatic cancer-induced diabetes from the more common type 2 diabetes. Although several clinical features and potential biomarkers have been investigated, optimal strategies and modalities to screen pancreatic cancer among the new-onset diabetes have not yet been fully determined.

Keywords: New-onset diabetes, Pancreatic cancer, Diabetogenic factor, Early detection

References

1. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011; 22:189–197.

2. Li D. Diabetes and pancreatic cancer. Mol Carcinog. 2012; 51:64–74.

3. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a metaanalysis of cohort studies. Eur J Cancer. 2011; 47:1928–1937.

4. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013; 42:198–201.

5. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a metaanalysis of 36 studies. Br J Cancer. 2005; 92:2076–2083.

6. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006; 166:1871–1877.

7. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A metaanalysis. JAMA. 1995; 273:1605–1609.

8. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas. 2003; 27:143–149.

9. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol. 2010; 20:92–98.

10. Ding XZ, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000; 21:310–320.

11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304–1305.

12. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137:482–488.

13. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-cou-pled receptor signaling systems: a novel target for the anti-diabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010; 16:2505–2511.

14. Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst. 2002; 94:1293–1300.

15. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005; 294:2872–2878.

16. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008; 114:23–37.

17. Kornmann M, Maruyama H, Bergmann U, et al. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res. 1998; 58:4250–4254.

18. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8:915–928.

19. Han L, Ma Q, Li J, et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and trans-activation of EGFR. PLoS One. 2011; 6:e27074.

20. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer. 2012; 19:F9–F26.

21. Bao Y, Giovannucci EL, Kraft P, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013; 105:95–103.

22. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134:95–101.

23. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008; 134:981–987.

24. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993; 80:1047–1050.

25. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986; 203:77–81.

26. Ding X, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998; 114:130–138.

27. Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta. 2006; 372:120–128.

28. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001; 121:640–645.

29. Pfeffer F, Koczan D, Adam U, et al. Expression of connexin26 in islets of Langerhans is associated with impaired glucose tolerance in patients with pancreatic adenocarcinoma. Pancreas. 2004; 29:284–290.

30. Huang H, Dong X, Kang MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol. 2010; 105:1661–1669.

31. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011; 11:279–294.

32. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas. 2011; 40:339–351.

33. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreato-graphic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002; 94:2344–2349.

34. Damiano J, Bordier L, Le Berre JP, et al. Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab. 2004; 30:203–207.

35. Lee JH, Kim SA, Park HY, et al. New-onset diabetes patients need pancreatic cancer screening? J Clin Gastroenterol. 2012; 46:e58–e61.

TOOLS

Similar articles